Thanks vetschoice, I wasn’t aware of that sunset clause.
Digging a bit more, I note that it has been proposed to extend the rare paediatric disease priority review voucher system for another three years (and also to apply it only to serious diseases) as part of the 21st Century Cures legislation (Sec. 2152).
That bill passed through the House of Representatives last month with high levels of bipartisan support and is now before the Senate. Voting on the bill is expected to take place either later this year or early next year.
http://www.raps.org/Regulatory-Focu...-to-Know-About-FDA’s-Priority-Review-Vouchers/
https://www.congress.gov/bill/114th-congress/house-bill/6
- Forums
- ASX - By Stock
- NEU
- Rare paediatric disease priority review
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.97%
!
$17.29

Rare paediatric disease priority review, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$17.29 |
Change
0.660(3.97%) |
Mkt cap ! $2.178B |
Open | High | Low | Value | Volume |
$16.80 | $17.34 | $16.63 | $9.078M | 529.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1334 | $17.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.33 | 2245 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1334 | 17.180 |
1 | 1000 | 17.020 |
3 | 693 | 17.000 |
1 | 1600 | 16.950 |
1 | 2000 | 16.930 |
Price($) | Vol. | No. |
---|---|---|
17.330 | 2245 | 3 |
17.340 | 1130 | 2 |
17.380 | 2350 | 2 |
17.400 | 4462 | 3 |
17.430 | 7 | 1 |
Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |